A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial

Copland, M. et al. (2023) A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. British Journal of Haematology, (doi: 10.1111/bjh.19220) (PMID:38016651) (Early Online Publication)

[img] Text
309444.pdf - Published Version
Available under License Creative Commons Attribution.

513kB

Abstract

Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN), in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. 202 patients randomised 1:1 were evaluable. Overall response rate (CR+CRi) was higher for LDAC+LEN versus LDAC (26% and 13.7%, respectively, P=0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC+LEN and LDAC, respectively). Addition of LEN was associated with increased toxicity and supportive care requirements.

Item Type:Articles
Additional Information:Funding: We are grateful to the NIHR for supporting local trial delivery, Blood Cancer UK for research support, the Haematology Clinical Trials Unit and Centre for Trials Research, Cardiff University for managing the trial and Celgene for providing drug and additional support for this Investigator Initiated Trial.
Status:Early Online Publication
Refereed:Yes
Glasgow Author(s) Enlighten ID:Burnett, Professor Alan and Copland, Professor Mhairi
Authors: Copland, M., Ariti, C., Thomas, I. F., Upton, L., Sydenham, M., Mehta, P., Islam, S., Kjeldsen, L., Burnett, A. K., Hills, R. K., Russell, N., and Dennis, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:British Journal of Haematology
Publisher:Wiley
ISSN:0007-1048
ISSN (Online):1365-2141
Published Online:28 November 2023
Copyright Holders:Copyright © 2023 The Authors
First Published:First published in British Journal of Haematology 2023
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record